Syfon Medical™
Syfon™ is bringing comprehensive gastric screening to the 80% of the world that has none. A smart pill that detects pre-cancer, H. pylori, GI bleeding, and more through AI-enhanced cytometry. No endoscopy, no sedation, no specialist required. Designed to turn any primary care setting into a detection center.
“Gastric cancer is the third leading cause of cancer death worldwide, yet the majority of cases are diagnosed too late for effective treatment.”
We dramatically improve survival rates through screening and surveillance by making early detection accessible, affordable, and patient-friendly.
Syfon™ core technology was developed by leading researchers at the University of Washington, a global hub for biomedical innovation. This novel diagnostic system enables the collection of stomach lining cells without sedation or full endoscopy. Designed for use anywhere from GI clinics to rural population screening programs, the 5 minute minimally invasive procedure supports cytological and molecular analysis for gastric diseases that currently take 800,000 lives every year. At an accessible cost per test, Syfon™ is creating a platform built for scale, not scarcity.
-
![]()
Aadil Diwan
Co-Founder & Chief Executive Officer
-
![]()
Eric J. Seibel, Ph.D.
Co-Founder & Chief Scientific Officer
-
![]()
Per Reinhall, Ph.D.
Co-Founder & Chief Technology Officer
Contact Us
Interested in collaborating? Share your details and a member of our team will be in touch shortly.